Expression of Minichromosome Maintenance Protein 2 As a Marker for Proliferation and Prognosis in Diffuse Large B-cell Lymphoma: a Tissue Microarray and Clinico-pathological Analysis

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2005 Dec 22

PMID 16368013

Citations 17

Authors

Ellen C Obermann

Philip Went

Annette Zimpfer

Alexandar Tzankov

Peter J Wild

Robert Stoehr

Stefano A Pileri

Stephan Dirnhofer

Affiliations

Soon will be listed here.

Abstract

Background: Minichromosome maintenance (MCM) proteins are essential for the initiation of DNA replication and have been found to be relevant markers for prognosis in a variety of tumours. The aim of this study was to assess the proliferative activity of diffuse large B-cell lymphoma (DLBCL) in tissue microarray (TMA) using one of the minichromosome maintenance proteins (Mcm2) and to explore its potential value to predict prognosis.

Methods: Immunohistochemistry for Mcm2 was performed on TMAs constructed from 302 cases of DLBCL. A monoclonal mouse antibody was used after heat induced antigen retrieval. Mcm2 expression was scored quantitatively. Positivity for Mcm2 was defined as presence of nuclear expression of Mcm2 in greater than or equal to 40 % of tumour cells. A statistical analysis was carried out of the association of Mcm2 and the clinico-pathological characteristics.

Results: Mcm2 expression was clearly evident in the nuclei of proliferating non-neoplastic cells and tumour cells. Positivity for Mcm2 was found in 46% (98/211) of analysable cases. A significant correlation existed between Mcm2 expression and presence of bulky disease (p = 0.003). Poor disease specific survival was observed in patients with DLBCL positive for Mcm2 expression in the univariate analysis (p = 0.0424).

Conclusion: Mcm2 expression can be used to assess tumour proliferation and may be useful as an additional prognostic marker to refine the prediction of outcome in DLBCL.

Citing Articles

MCM-2 Levels as a Potential Biomarker for Predicting High-Risk Breast Cancer Patients According to TAILORx Classification.

Unal C, Ozmen T, Ilgun A, Ordu C, Ozkurt E, Ak N Breast Cancer (Dove Med Press). 2023; 15:659-669.

PMID: 37674872 PMC: 10478780. DOI: 10.2147/BCTT.S421535.

Proteomic Portrait of Human Lymphoma Reveals Protein Molecular Fingerprint of Disease Specific Subtypes and Progression.

Ku X, Wang J, Li H, Meng C, Yu F, Yu W Phenomics. 2023; 3(2):148-166.

PMID: 37197640 PMC: 10110798. DOI: 10.1007/s43657-022-00075-w.

DNA replication: Mechanisms and therapeutic interventions for diseases.

Song H, Shen R, Mahasin H, Guo Y, Wang D MedComm (2020). 2023; 4(1):e210.

PMID: 36776764 PMC: 9899494. DOI: 10.1002/mco2.210.

Evaluation of the Synergistic Potential of Simultaneous Pan- or Isoform-Specific BET and SYK Inhibition in B-Cell Lymphoma: An In Vitro Approach.

Sender S, Sultan A, Palmer D, Koczan D, Sekora A, Beck J Cancers (Basel). 2022; 14(19).

PMID: 36230614 PMC: 9564024. DOI: 10.3390/cancers14194691.

Low BACH2 Expression Predicts Adverse Outcome in Chronic Lymphocytic Leukaemia.

Ciardullo C, Szoltysek K, Zhou P, Pietrowska M, Marczak L, Willmore E Cancers (Basel). 2022; 14(1).

PMID: 35008187 PMC: 8750551. DOI: 10.3390/cancers14010023.

References

Moller M, Kania P, Ino Y, Gerdes A, Nielsen O, Louis D . Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A. Leukemia. 2000; 14(5):898-904. DOI: 10.1038/sj.leu.2401761. View

Verheijen R, Kuijpers H, Schlingemann R, Boehmer A, VAN Driel R, Brakenhoff G . Ki-67 detects a nuclear matrix-associated proliferation-related antigen. I. Intracellular localization during interphase. J Cell Sci. 1989; 92 ( Pt 1):123-30. DOI: 10.1242/jcs.92.1.123. View

Burger P, Shibata T, Kleihues P . The use of the monoclonal antibody Ki-67 in the identification of proliferating cells: application to surgical neuropathology. Am J Surg Pathol. 1986; 10(9):611-7. DOI: 10.1097/00000478-198609000-00003. View

Tye B . MCM proteins in DNA replication. Annu Rev Biochem. 2000; 68:649-86. DOI: 10.1146/annurev.biochem.68.1.649. View

Xue W, Khoo U, Ngan H, Chan K, Chiu P, Tsao S . Minichromosome maintenance protein 7 expression in gestational trophoblastic disease: correlation with Ki67, PCNA and clinicopathological parameters. Histopathology. 2003; 43(5):485-90. DOI: 10.1046/j.1365-2559.2003.01728.x. View

Miller T, Grogan T, Dahlberg S, Spier C, Braziel R, Banks P . Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood. 1994; 83(6):1460-6. View

Romanowski P, Madine M . Mechanisms restricting DNA replication to once per cell cycle: MCMS, pre-replicative complexes and kinases. Trends Cell Biol. 1996; 6(5):184-8. DOI: 10.1016/0962-8924(96)10015-5. View

Freeman A, Morris L, Mills A, Stoeber K, Laskey R, Williams G . Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res. 1999; 5(8):2121-32. View

Shipp M, Ross K, Tamayo P, Weng A, Kutok J, Aguiar R . Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002; 8(1):68-74. DOI: 10.1038/nm0102-68. View

10.

Meng M, Grossfeld G, Williams G, DILWORTH S, Stoeber K, Mulley T . Minichromosome maintenance protein 2 expression in prostate: characterization and association with outcome after therapy for cancer. Clin Cancer Res. 2001; 7(9):2712-8. View

11.

Brown D, Gatter K . Ki67 protein: the immaculate deception?. Histopathology. 2002; 40(1):2-11. DOI: 10.1046/j.1365-2559.2002.01343.x. View

12.

Moller M, Nielsen O, Pedersen N . Cyclin D3 expression in non-Hodgkin lymphoma. Correlation with other cell cycle regulators and clinical features. Am J Clin Pathol. 2001; 115(3):404-12. DOI: 10.1309/8KF0-0Y0C-2F4L-UHXL. View

13.

Kato H, Miyazaki T, Fukai Y, Nakajima M, Sohda M, Takita J . A new proliferation marker, minichromosome maintenance protein 2, is associated with tumor aggressiveness in esophageal squamous cell carcinoma. J Surg Oncol. 2003; 84(1):24-30. DOI: 10.1002/jso.10287. View

14.

Cheung A, Ngan H, Collins R, Wong Y . Assessment of cell proliferation in hydatidiform mole using monoclonal antibody MIB1 to Ki-67 antigen. J Clin Pathol. 1994; 47(7):601-4. PMC: 502073. DOI: 10.1136/jcp.47.7.601. View

15.

Stoeber K, Mills A, Kubota Y, Krude T, Romanowski P, Marheineke K . Cdc6 protein causes premature entry into S phase in a mammalian cell-free system. EMBO J. 1998; 17(24):7219-29. PMC: 1171068. DOI: 10.1093/emboj/17.24.7219. View

16.

Toschi L, Bravo R . Changes in cyclin/proliferating cell nuclear antigen distribution during DNA repair synthesis. J Cell Biol. 1988; 107(5):1623-8. PMC: 2115310. DOI: 10.1083/jcb.107.5.1623. View

17.

Obermann E, Eward K, Dogan A, Paul E, Loddo M, Munson P . DNA replication licensing in peripheral B-cell lymphoma. J Pathol. 2005; 205(3):318-28. DOI: 10.1002/path.1695. View

18.

Davies R, Freeman A, Morris L, Bingham S, Dilworth S, Scott I . Analysis of minichromosome maintenance proteins as a novel method for detection of colorectal cancer in stool. Lancet. 2002; 359(9321):1917-9. DOI: 10.1016/S0140-6736(02)08739-1. View

19.

Ritzi M, Baack M, Musahl C, Romanowski P, Laskey R, Knippers R . Human minichromosome maintenance proteins and human origin recognition complex 2 protein on chromatin. J Biol Chem. 1998; 273(38):24543-9. DOI: 10.1074/jbc.273.38.24543. View

20.

Hall P, Levison D . Review: assessment of cell proliferation in histological material. J Clin Pathol. 1990; 43(3):184-92. PMC: 502326. DOI: 10.1136/jcp.43.3.184. View